Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Healthy Volunteer

Treatments: Drug: AZD7268; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00796965

D1151C00001

Details and patient eligibility

About

Single Ascending Dose Study

Enrollment: 48 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Provision of Informed Consent
• Healthy male subjects and female subjects (of non-child bearing potential) with suitable veins for cannulation or repeated venipuncture

Exclusion criteria

• Inability to understand or cooperate with given information
• Positive human immune deficiency virus (HIV), Hepatitis B, or Hepatitis C test
• Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology, and urinanalysis

Trial design

48 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: AZD7268

2

Placebo Comparator group

Treatment:

Drug: Placebo